Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA)
Solicitation from the National Institutes of Health. Due Oct 21, 2026, 3:00 PM (UTC-4), 3 days left.
| Solicitation number | ARPA-H-SOL-26-163 |
|---|---|
| Agency | National Institutes of Health |
| Office | Advanced Research Projects Agency for Health (ARPA-H) |
| Notice type | Solicitation |
| Set-aside | None |
| Trade (NAICS) | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715) |
| Product or service code | AN13 |
| Posted | Oct 14, 2026 |
| Response deadline | Oct 21, 2026, 3:00 PM (UTC-4) (3 days left) |
Official notice and attachments
Description
Amendment 1 (10/14/2026): Update due dates and/or times of all TAs SPECTRA will identify and act on autism trajectories, the evolving developmental paths individuals follow across the lifespan from the prenatal period through aging, spanning autism characteristics, co-occurring conditions, and functional outcomes together with the genetic, biological, behavioral, iatrogenic (medical influences), environmental factors and their nonlinear interactions.
Rather than examining these factors in isolation, SPECTRA will examine how they combine and interact, including their nonlinear interactions, to produce autism and its co-occurring conditions over time. SPECTRA will also develop technologies that serve two purposes at once: extending reliable assessment beyond the clinic while improving everyday communication, function, and quality of life.
The same tools people use to live more fully will also generate the data that drive measurement and personalized care.
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.